Magnesium + ashwagandha gummy projects need two identity systems, not one marketing blend.
Before a useful quote, define elemental magnesium from the selected compound and define ashwagandha by botanical identity, plant part, preparation and marker-assay basis. Then evaluate the combined material load, serving, sensory system, methods, package and proposed U.S. claims as one project.
This is a custom-project service page, not a stocked formula or proof that any requested ingredient, dose, claim, MOQ or schedule is feasible.
Buyer Decision MapThe fields that make competing supplier quotes comparable
These are buyer inputs and review gates. This page does not identify an approved Sucotond magnesium material, ashwagandha ingredient, formula, assay result or shelf life.
| Decision field | What the project brief must define | Why it changes feasibility |
|---|---|---|
| Magnesium source | Exact compound, supplier, grade, specification and analyte basis | The same elemental target can require different input mass and method details. |
| Elemental magnesium | Declared amount per serving and calculation from approved material data | Supplement Facts uses elemental magnesium, not total compound weight. |
| Ashwagandha identity | Withania somnifera, plant part, extract or powder status, ratio, extraction information and carrier | Different preparations are not interchangeable by common name. |
| Marker specification | Named marker, assay basis, method, units and acceptance criteria | “Withanolides” without method and basis is not a complete transfer specification. |
| Serving architecture | Amount of each ingredient, pieces per serving and target piece mass | Total solids and piece count affect chew, taste and manufacturing headroom. |
| Sensory criteria | Mineral character, botanical bitterness or astringency, flavor, aftertaste and appearance | The combined matrix must be approved as a whole. |
| Testing plan | Raw-material identity, component specifications, finished-product assay, contaminants, microbiology and stability | Each result needs a defined sample, method, unit and acceptance rule. |
| Label and claims | Market, Supplement Facts basis, ingredient naming, proposed express and implied claims, disclaimers and cautions | Formula and marketing evidence must be reviewed before artwork release. |
| Package and commercial unit | Count, closure, induction seal, desiccant if evaluated, case pack, annual volume, destination and launch window | MOQ, timing and price depend on the actual commercial configuration. |
Three shortcuts that produce weak RFQs
Using compound mass as label magnesium
NIH's Office of Dietary Supplements explains that a supplement label declares elemental magnesium. The buyer brief therefore needs both the elemental target and the selected source specification; a compound name alone does not close the calculation.
Calling every extract “ashwagandha”
NCCIH notes that supplements use different parts and preparations. A transferable specification identifies the Latin botanical, plant part and preparation, while a marker claim also needs its own assay basis.
Copying an ingredient story onto a finished gummy
FDA and FTC principles require truthful, non-misleading claims with appropriate substantiation. A supplier brochure, disclaimer or ingredient-level paper does not automatically substantiate every express or implied finished-product message.
Build the release package before the label promise
The exact scope is project-specific. FDA's dietary-supplement CGMP guidance describes identity confirmation and specification controls; it does not establish a result for this proposed product.
1. Incoming materials
Record supplier, lot, identity method, specification, COA fields and supplier-qualification basis for each dietary ingredient. Define how the magnesium basis and botanical identity will be confirmed.
2. Formula and finished batch
Predefine analyte, sample preparation, method suitability, units, acceptance criteria, contaminant and microbiological scope. Do not assume two separate ingredient methods work unchanged in the combined gummy matrix.
3. Stability and change control
Connect time points, storage conditions, package configuration and acceptance criteria. A change in source, extract, flavor, process or package reopens the affected risk and evidence decisions.
Use the gummy product specification checklist to structure the formula fields, then map every requested document in the project evidence register. If magnesium is not part of the formula, use the standalone ashwagandha gummy sourcing brief so botanical identity and marker controls stay central.
Primary sources used for this buyer framework
These references guide scoping and review. They do not approve a formula, claim, label or supplier.
Ingredient and label basis
NIH ODS: Magnesium — Health Professional Fact Sheet
NCCIH: Ashwagandha
USP–NF: Ashwagandha Root monograph
Reference review date: September 1, 2026. This page provides procurement context, not medical or legal advice.
Questions to resolve before sampling
Does magnesium compound weight equal the magnesium declared on the label?
No. The Supplement Facts declaration is based on elemental magnesium. The project calculation must reconcile the requested elemental amount with the approved ingredient specification.
Is every ashwagandha ingredient interchangeable?
No. The botanical name, plant part, preparation, extract ratio, solvent or carrier information and marker assay basis can differ. The exact ingredient must be identified before feasibility and testing are evaluated.
Can a sleep or stress claim be assumed for this combination?
No. Proposed label and advertising claims require product-specific legal and substantiation review. This service page makes no finished-product health claim.
What should a buyer send for a useful first review?
Send the magnesium compound and elemental target, ashwagandha identity and specification, amount per serving, piece count, market, proposed claims, package, annual volume and required test panel.
Send the combination brief—not just the ingredient names.
Include what is known and mark open decisions. The Brooklyn office will coordinate a preliminary, non-confidential review; feasibility, documents and commercial terms are confirmed only for the resulting project scope.
Brooklyn, NY 11214